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Abstract: We previously discovered suppressor T cell-derived, antigen (Ag)-specific exosomes
inhibiting mouse hapten-induced contact sensitivity effector T cells by targeting antigen-presenting
cells (APCs). These suppressive exosomes acted Ag-specifically due to a coating of antibody
free light chains (FLC) from Ag-activated B1a cells. Current studies are aimed at determining if
similar immune tolerance could be induced in cutaneous delayed-type hypersensitivity (DTH) to
the protein Ag (ovalbumin, OVA). Intravenous administration of a high dose of OVA-coupled,
syngeneic erythrocytes similarly induced CD3+CD8+ suppressor T cells producing suppressive,
miRNA-150-carrying exosomes, also coated with B1a cell-derived, OVA-specific FLC. Simultaneously,
OVA-immunized B1a cells produced an exosome subpopulation, originally coated with Ag-specific
FLC, that could be rendered suppressive by in vitro association with miRNA-150. Importantly,
miRNA-150-carrying exosomes from both suppressor T cells and B1a cells efficiently induced
prolonged DTH suppression after single systemic administration into actively immunized mice,
with the strongest effect observed after oral treatment. Current studies also showed that OVA-specific
FLC on suppressive exosomes bind OVA peptides suggesting that exosome-coating FLC target
APCs by binding to peptide-Ag-major histocompatibility complexes. This renders APCs capable of
inhibiting DTH effector T cells. Thus, our studies describe a novel immune tolerance mechanism
mediated by FLC-coated, Ag-specific, miRNA-150-carrying exosomes that act on the APC and are
particularly effective after oral administration.
Keywords: antibody free light chains (FLC); delayed-type hypersensitivity (DTH); extracellular
vesicles (EVs); exosomes; miRNA; miRNA-150; oral therapy; suppressor T cells
1. Introduction
Recent studies have shown that immune regulation in vivo is more diverse than previously
appreciated. A unique antigen (Ag)-specificity of T cell immunosuppression was described previously
in contact sensitivity (CS) induced by epicutaneous immunization of mice with reactive hapten [1–5].
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This form of Ag-specific T cell tolerance is systemically generated by intravenous (IV) administration
of high doses of hapten-conjugated syngeneic erythrocytes, followed by skin sensitization with the
same reactive hapten. This induces CD8+ suppressor T cells (Ts) that are not FoxP3+ regulatory T cells
(Treg) [4].
The Ts cells produce and release suppressive, Ag-specific extracellular vesicles (EVs),
namely exosome-like nanovesicles [4], that deliver inhibitory miRNA-150. Exosome-targeted
antigen-presenting cells (APC), in turn, suppressed the CS effector T cells [4,6]. Exosome-mediated
suppression was unequivocally confirmed by an in vivo experiment, showing that systemic
administration of these exosomes to actively sensitized hosts at the peak of the hapten-specific
effector T cell-mediated CS strongly reduced subsequent immune skin swelling responses measured
for over four days [4].
The Ag-specificity of this Ts cell-derived exosome-mediated suppression is due to a surface
coating with antibody (Ab) free light chains (FLC) provided by B1a cells that also were activated
during tolerogenesis [4]. This Ag-specificity of suppressive exosomes was proved in dual Ag crisscross
experiments using two non-cross reactive haptens, and also in similar dual crisscross Ag-affinity
column chromatography [4].
We showed previously that contact immunization rapidly activates a subpopulation of Ag-specific
peritoneal B1a cells to migrate to the spleen, where they produce specific IgM Ab and their derived
Ab FLC [7]. By tolerizing µMT and JHneg/neg antibody deficient mice, and coating the resulting
exosomes with chosen FLC, we demonstrated that the Ag-specific Ab FLC bind to the surface of Ts
cell-derived exosomes. This in turn is responsible for the Ag-specificity of the exosome targeting of
CS effector cells [8]. Furthermore, the B1a cells also release non-suppressive exosomes, that already
express Ag-specific B cell receptor (BCR) and/or surface Ab FLC [9]. Consequently, we have uniquely
shown that in vitro association of these Ag-specific B1a cell-derived exosome-like nanovesicles with
miRNA-150, but not control miRNAs, also renders them suppressive. Their effect is similar to the
exosomes induced in the Ts-cells of Ag-tolerized mice, that endogenously acquired miRNA-150. This
was termed “an alternate Ag-specific exosome-mediated suppression pathway” [10].
Results of these prior studies on CS suppression led to the conclusion that in vivo these Ag-specific
B1a cell-derived exosomes can associate with exogenous inhibitory non-exosomal miRNA, perhaps
carried in vivo by RNA-binding argonaute proteins [4]. Consequently, such miRNA-150-associated
exosomes were strongly inhibitory against CS effector cells [4]. Therefore, it seemed that this miRNA
likely was acquired from the freely circulating, extracellular pool of non-exosomal RNAs protected from
RNases by chaperones like Argonaut proteins [4]. As an in vivo consequence, these B1a cell-derived
exosomes seem able to act indirectly by similar Ag-specific binding to surface Ag of APCs, that then
inhibit CS-effector T cells via transfer of their acquired inhibitory miRNA-150 [10].
Given the demonstrated initial suppressive exosome targeting of the APC in CS [6], it was
postulated that the actual Ag bound by these FLC-coated suppressive exosomes could be hapten
chemically conjugated to self-protein-peptides complexed with MHC on the APC surface, but that
could not be determined in the hapten CS system. In the current study, we sought to determine if similar
suppression mechanisms applied to classical cutaneous delayed-type hypersensitivity (DTH) induced
by ovalbumin (OVA) protein Ag. In this case, it was postulated could show that that exosome-coating
FLC might bind target OVA Ag peptide determinants complexed with MHC on the APC surface.
The most definitive experiments were administering suppressive exosomes systemically to actively
immunized mice at the peak of the skin responses and determining effects on elicited DTH over
subsequent days [4]. Surprisingly, the resulting long term systemic suppression resulting from oral
administration of either the T or B cell-derived suppressive exosomes was superior to intravenous (IV)
or intraperitoneal (IP) injections.
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2. Results
2.1. Intradermal Immunization with OVA Induces DTH Effector Cells
Mice were immunized for induction of protein Ag-specific DTH by ID injections of a high dose
of OVA (100 µg) without an adjuvant. This allowed elicitation of classical late 24 h DTH responses
to ID ear injection (challenge) with a low dose of OVA (10 µg) on day four (Protocol, Figure S1A),
compared to controls just immunized with PBS and again similarly ear challenged with 10 µg OVA
(Protocol, Figure S1B). The DTH response consisted of an initial, weakly Ag-specific, early, edematous
ear swelling component, peaking at 2 h after challenge (Figure S1C), shown previously to be due to B1a
cell-derived IgM Ab and their derived Ab FLC [9,11]. This early component is required for elicitation
of the subsequent classical, Ag-specific, late inflammatory phase, that peaks 24 h after skin challenge
(Figure S1D) [7,9,11]. Three OVA ID immunizing doses were used (20, 100, and 500 µg). For this
dose range, the intensity of elicited DTH, measured as 24 h ear swelling response [12], was similar
(Figure S1D, Groups B, C, and D vs. A). Thus, we chose 100 µg of OVA in saline as the optimal
immunizing dose administered by ID injection into four sites, as previously described [11].
2.2. Adoptively Transferred DTH-Effector Cells Were Strongly Inhibited by Incubation In Vitro with Ts Cells
That Produced Suppressive Exosomes
Immune tolerance was induced by IV injection on day 0 and 4 of high doses of OVA Ag linked to
syngeneic red blood cells (RBC), followed by OVA ID injection on days 8 and 9 (Protocol, Figure S2A).
As tolerogen, OVA was coupled to syngeneic RBC in the presence of either Chromium Cl (Cr3+) or
EDC (Figure S2B, 53% suppression), and EDC was chosen as the optimal coupling agent.
Inhibition of DTH by the tolerogenic procedure was found to be due to generation of Ts cells.
One way to show this was by adoptive transfer of DTH effector cells harvested from the ID optimally
immunized mice that often were employed as a positive response for testing of Ts cell suppressive
exosome activity (Protocol, Figure S2C and Figure S2D, left half). Their suppressor activity was
determined by in vitro combining and briefly incubating the Ts cells, or their derived exosomes,
with the DTH-effector cells just before the adoptive transfer. Suppression was assayed by inhibition
of the co-adoptively transferred OVA DTH-effector cells. This was quantitated by measurement of
elicited ear swelling activity of the DTH-effector cells in naive recipients that were ear challenged with
the low dose of OVA (Protocol, Figure S2D, right half).
2.3. Ts Cell Suppression Was due to Production of Suppressive EVs that by Surface Expression of Tetraspanins
Are Common Small Exosome EVs, and Uniquely also Co-Express Surface Ab FLC
The Ts cells were collected from Ag-tolerized mice on day 11 by harvesting and pooling lymph
node and spleen cells. These cells were then cultured for 48 h to yield supernatant containing the
suppressive exosomes (Figure 1A). This combination of IV and ID Ag tolerizing injections of OVA
generated OVA-specific Ts cells that released OVA-specific suppressive exosomes able to inhibit
adoptive transfer of the DTH effector cells (Figure 1A, Group B vs. A, 80% suppression). Furthermore,
we previously showed in hapten-induced CS that the Ts cells from hapten tolerized mice are CD3+
and CD8+ [4]. Similarly, in the current OVA DTH system, there also was loss of exosome-suppressive
activity when either CD3+ or CD8+ populations from the mixed lymph node and spleen cells of
mice tolerized with IV OVA-RBC, were depleted with specific IgG monoclonal antibodies (mAb) and
complement (Figure 1B).
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Figure 1. OVA Ag-specific Ts cell-derived, CD9+ exosomes inhibit adoptive transfer of T cell mediated 
DTH. (A) OVA Ag-specific suppressor T cell-derived exosomes inhibit OVA-immune DTH effector 
cells (Group B, 80% suppression) undergoing adoptive transfer of DTH (Group A, immune response 
control). (B) Lymph node and spleen cells of Ag-tolerized mice failed to produce suppressive 
exosomes when depleted of CD3+ (Group C) and CD8+ (Group D) cell populations vs. their exosome 
suppression control (Group B, 95% suppression). (C) Flow cytometry showing that OVA-specific Ts 
cell-derived exosomes express CD9, CD63 (weakest expression), and CD81 tetraspanins, as well as 
antibody kappa light chains (left and center), and simultaneously co-express CD9 and antibody light 
chains (right). (D) OVA-specific suppressive exosomes were analyzed with transmission electron 
microscopy, that showed the presence of nanovesicles with bilamellar membranes. (E) Nanoparticle 
tracking analysis of OVA-specific Ts cell-derived exosomes to estimate their size and concentration. 
(F) OVA-specific suppressive exosomes were separated onto an anti-CD9-affinity chromatography 
column. The resulting anti-CD9 binding and non-binding exosome fractions were then used to treat 
OVA DTH effector cells prior to their adoptive transfer into naive recipients that 24 h later were 
challenged with OVA. The elicited DTH ear swelling responses were measured 24 h later with an 
engineer’s micrometer, showing that the full suppressive activity of the Ts cell-derived exosomes was 
in the anti-CD9 binding and eluted fraction (about 10% of the total) and there was no suppressive 
activity in the non-binding flow through fraction (Group D vs. C, 71% suppression vs. 0% 
suppression). (G) Nanoparticle tracking analysis of OVA-specific Ts cell-derived exosomes present in 
the eluate fraction resulting from separation onto an anti-CD9 affinity chromatography column, to 
estimate their size and concentration. Results of in vivo assays are shown as delta ± standard error 
(SE), one-way ANOVA with post hoc RIR Tukey test. n = 5 mice in each group or three samples in 
each experimental repetition. 
In addition to biological activity, the descriptive characteristics and properties—like phenotype 
of the assayed OVA Ag-specific suppressive exosomes—resembled the hapten-specific exosome-like 
nanovesicles isolated from mice tolerized to hapten and also were produced by CD3+ and CD8+ T 
cells [4]. OVA-specific exosomes highly expressed CD9 and CD81 tetraspanins with significantly 
lower expression of CD63 (Figure 1C). Noteworthy for the current OVA system, all of the exosomes 
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control (Group B, 95% suppression). (C) Flow cytometry showing that OVA-specific Ts cell-derived
exosomes express CD9, CD63 (weakest expression), and CD81 tetraspanins, as well as antibody kappa
light chains (left and center), and simultaneously co-express CD9 and antibody light chains (right).
(D) OVA-specific suppressive exosomes were analyzed with transmission electron microscopy, that
showed the presence of nanovesicles with bilamellar membranes. (E) Nanoparticle tracking analysis
of OVA-specific Ts cell-derived exosomes to estimate their size and concentration. (F) OVA-specific
suppressive exosomes were separated onto an anti-CD9-affinity chromatography column. The resulting
anti-CD9 binding and non-binding exosome fractions were then used to treat OVA DTH effector
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The elicited DTH ear swelling responses were measured 24 h later with an engineer’s micrometer,
showing that the full suppressive activity of the Ts cell-derived exosomes was in the anti-CD9 binding
and eluted fraction (about 10% of the total) and there was no suppressive activity in the non-binding
flow through fraction (Group D vs. C, 71% suppression vs. 0% suppression). (G) Nanoparticle
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expressing CD9 tetraspanin also co-expressed surface Ig FLC (Figure 1C, bottom center and right),
but here were obvious high (about 10%) and low expressing (about 90%) EV and even exosomes
of non-immune animals were slightly positive for the Ig FLC. In addition, transmission electron
microscopy revealed the presence of vesicles with billamelar membrane (Figure 1D), characterized by
average size around 150 nm, as determined by nanoparticle tracking analysis (Figure 1E). Importantly,
these Ts cell-derived exosomes were determined to be biologically active by isolation and then testing
for suppressive function of the subpopulation eluted from anti-CD9-linked affinity columns that was
strongly suppressive compared to the flow through fraction that did not bind to the anti-CD9 columns
(Figure 1F, Group D vs. C). Nanoparticle tracking analysis of OVA Ts cell exosomes eluted from the
anti-CD9 affinity column showed the presence of small EV in the column eluate (Figure 1G). Thus,
special phenotypic characteristics of small EVs, most likely exosomes, were surely linked to their
function. The linkage of phenotype and function is not often tested elsewhere. In addition, when
OVA-specific Ts cell-derived exosomes were separated on OVA-linked affinity column, they also
strongly suppressed adoptively transferred DTH response (Figure 2A).
In summary, all of these findings concerning phenotypic and descriptive properties of the OVA
Ts exosome EV, fit with the recent most thorough description of small EVs of endosomal origin,
i.e., exosomes [13]. We also have linked this phenotype to the suppressive function of EVs by testing of
their biological activity after separation on OVA Ag and anti-CD9 affinity columns (Figures 1F and 2A).
Therefore, we have classified the OVA-specific, Ts cell-derived, functionally active, suppressive
nanovesicles as exosomes, a small subtype of the vast family of EVs.
2.4. In Vivo Testing of Ag-Specificity of the Ts Cell-Derived Exosomes
Expression of FLC and binding to OVA in Ag-affinity chromatography suggested the Ag-specificity
of Ts cell-derived exosome action. By employing of Ts cell-derived exosomes induced by the
antigenically non-cross reactive protein keyhole limpet hemocyanin (KLH), we have shown that the
exosome suppression is Ag-specific. In this case, KLH-specific exosomes harvested from lymphoid
cells of mice identically tolerized to KLH, and similarly IP injected into actively OVA-immunized mice
just after the peak of the active 24-h OVA-induced DTH response, were totally inactive (Figure 2B).
In contrast, Ts cell-derived exosomes harvested from mice tolerized by IV injection of high doses of
OVA-RBC (Figure S2A), Ag-specifically inhibited DTH in mice actively immunized with OVA, when
delivered systemically IP just before, and, most importantly, 24 h after ear challenge with Ag (Figure 3).
It thus seems that Ag-specificity of exosome mediated suppression likely resulted from the presence of
antibody kappa light chains on the Ts-derived exosome surface that enabled Ag-specific binding to the
OVA Ag-linked sepharose in the affinity column (Figures 1C and 2A) [8].
2.5. Role of Antigen-Presenting Macrophages in Exosome-Mediated Suppression
Ts cell-derived exosomes that had bound to OVA Ag-linked Sepharose columns were found to
suppress DTH effector cells (Figure 2A), suggesting that APCs may be targeted by these exosomes.
In fact, previous studies on suppression of hapten-induced CS showed that Ag-presenting macrophages
are targeted by the Ts cell-derived exosomes, that in turn inhibited the DTH-effector T cells [6]. Thus,
in the hapten Ag system, the Ts cell-derived exosome mediated suppression depended on the presence
of macrophages acting as APC for the effector T cells [6]. In the current study, we have similarly
observed that depletion of macrophages abolishes the suppression in mice tolerized by IV injection
of high doses OVA-RBC (Figure 2C, Group C vs. D). This confirms the crucial role of Ag-presenting
macrophages for Ag-specific suppressive exosom targeting also applies to the exosome-mediated
suppression of OVA-induced DTH.
This experiment shows further that depletion of macrophages also caused decreased DTH-ear
swelling responses in actively OVA DTH immunized mice (Figure 2C, Group C vs. A). Therefore,
this additionally demonstrates the important role of macrophages acting as APC for the development
of the optimal late effector phase of OVA-induced DTH. Thus, for calculations, considering this
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decreased response in macrophage-depleted actively sensitized hosts as a 100% DTH response, similar
macrophage depletion before the elicitation of DTH in the animals that were OVA Ag-tolerized IV
prior to the second step of ID immunization, caused a complete reversal of that suppression (Figure 2C,
Group D vs. C). Therefore, these data indicate that the tolerogenesis and, as expected, the ability to
suppress active DTH, both depend on Ag-presenting macrophages.Int. J. Mol. Sci. 2020, 21, 5540 6 of 34 
 
 
Figure 2. Ag specificity of suppressive exosomes shown by OVA Ag affinity chromatography and 
criss-cross Ag-testing, and the essential role of antigen-primed macrophages in tolerance induction. 
(A) OVA-induced DTH is suppressed only by exosomes present in the eluate of OVA Ag-affinity 
chromatography column separating the exosomes (Group D column eluate vs. Group C column flow 
through, 90% suppression vs. 0% suppression). (B) Ag specificity of suppressive exosome treatment 
employing analogous anti-KLH protein suppressor T cell exosomes from KLH Ag tolerized donors, 
that do not inhibit OVA DTH when given IP at the 24-h peak of the OVA-elicited DTH ear swelling 
response. (C) OVA-induced DTH cannot be suppressed by intravenous tolerization with systemic 
administration of high doses of OVA-linked syngeneic red blood cells in mice depleted of antigen-
Figure 2. Ag specificity of suppressive exosom hown by OVA Ag affinity chrom tography and
criss-cross Ag-testing, and the essential role of antigen-primed macrophages in tolerance induction.
(A) OVA-induced DTH is suppressed only by exosomes present in the eluate of OVA Ag-affinity
chromatography column separating the exosomes (Group D column eluate vs. Group C column
flow through, 90% suppression vs. 0% suppression). (B) Ag specificity of suppressive exosome
treatment employing analogous anti-KLH protein suppressor T cell exosomes from KLH Ag tolerized
donors, that o o inhibit OVA DTH when given IP at the 24-h peak of th OVA-elicited DTH ear
swelling response. (C) OVA-induced DTH cannot be suppressed by intravenous tolerization with
systemic administration of high doses of OVA-linked syngeneic red blood cells in mice depleted of
antigen-presenting macrophages (Group D vs. C). Results are shown as delta ± standard error (SE),
one-way ANOVA with post hoc RIR Tukey test. n = 5 mice in each group.
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Figure 3. In vivo treatment of active OVA DTH with a systemically administered, single dose of
suppressor T cell-derived exosomes, given at various times, and by various routes, including oral
and intradermal (ID), with assessment of their Ag-specificity. (A) In vivo treatment of OVA-induced,
active DTH with OVA-specific, suppressive exosomes, administered IP at the time of immunization
on day 0, were not suppressive of subsequently elicited 24-h DTH ear swelling responses measured
over five days. (B) In vivo treatment of OVA-induced, active DTH with OVA-specific, suppressive
exosomes, administered IP just before elicitation of the DTH response by ear challenge on day 4,
were strongly suppressive (48–75% suppression over the subsequent five days). (C) Protocol: In vivo
treatment of active OVA DTH with systemically administered suppressor T cell exosomes, given
just after measurement of the 24-h maximum ear swelling response. (D) In vivo intraperitoneal (IP)
treatment of OVA active DTH with OVA-specific suppressor T cell-derived exosomes administered at
the 24-h peak of response, were strongly suppressive (48–75% suppression over the subsequent four
days). (E) Comparing intravenous (IV), IP, ID, and oral treatment of actively OVA DTH immunized
mice with OVA-specific suppressor T cell-derived exosomes; starting at the 24-h peak of response,
and measured over the subsequent four days; all significantly inhibited DTH ear swelling; especially
oral treatment (the red line). Results are shown as delta ± standard error (SE), one-way ANOVA with
post hoc RIR Tukey test. n = 5 mice in each group.
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2.6. OVA-Specific Ts Cell-Derived Suppressive Exosomes Can Strongly Inhibit Active OVA-Induced DTH
In Vivo
Besides demonstrating the suppression of the adoptively transferred DTH effector cells mixed
in vitro with Ts cells or their exosomes, we conducted clinically oriented in vivo experiments. For this
purpose, we injected the exosomes derived from the OVA tolerized Ts cells directly into mice with
active OVA-induced DTH. When systemically administered into mice via the IP route at the time of
immunization, the exosomes were only weakly and briefly inhibitory (Figure 3A). In contrast, they had
far greater suppressive activity when injected IP into actively immunized mice just before elicitation
of DTH on day 4 (Figure 3B). Most important were results obtained when systemic IP exosome
treatment began just after determining the peaking 24 h responses (Protocol, Figure 3C). In kinetic
testing, we found that the OVA-specific, Ts cell-derived exosomes strongly suppressed subsequent
daily continuing DTH responses up to 120 h (day 4) after IP administration of a single physiological
dose (Figure 3D). This experiment showed the clinically applicable in vivo suppressive activity of the
OVA-specific Ts cell-derived exosomes.
2.7. Comparison of IV, IP, ID, and PO Systemic Treatments with OVA Ts Cell-Derived Exosomes, Beginning
Just after the 24-Hour Peak of OVA DTH, in Actively Immunized Mice
In the studies described above, OVA-specific suppressive exosomes administered IP to actively
immunized mice significantly suppressed the in vivo manifestations of OVA DTH reactions
(Figure 3B,D). This systemic administration of the suppressive exosomes at a single dose by the
IP route, had not been compared to any other means of treatment. Therefore, we performed new
experiments to test the efficacy of treatment with Ts cell-derived, OVA-specific, suppressive exosomes
given by more clinically applicable routes; compared to IP treatment. Thus, these OVA-specific
suppressive exosomes again were administered systemically at a single dose judged to be physiological,
via different routes at the 24-h peak of response in mice that were actively OVA immunized to elicit DTH.
Administration of these exosomes via IP route again was quite suppressive over the subsequent 4
days (Figure 3E, green line) compared to positive control, i.e., untreated active DTH (Figure 3E, thick
black line). Furthermore, administering the exosomes IV also caused prolonged inhibition (Figure 3E,
blue line), but overall was slightly less effective compared with the IP route.
Outstandingly, the most efficient suppression was observed after PO administration of the single
dose of the inhibitory exosomes (Figure 3E, red line). Finally, and interestingly, when treatment
with the suppressive exosomes was by the ID route in the torso, this also caused suppression of the
DTH responses (Figure 3E, dashed black line). Note that this was via the same route used for Ag
immunization, but at different skin sites that also were distant from DTH elicited in the ears.
2.8. Non-Suppressive Ts Cell-Derived Exosomes from Tolerized miRNA-150neg/neg Mice Are Rendered
Suppressive by Association with miRNA-150
In the similar, previously studied tolerance system of the hapten-specific CS response, it was
shown that miRNA-150 was required to be carried into the targeted cells by the suppressive exosomes
for inhibitory activity [4]. We tested this point here by using exosomes generated by OVA-tolerized
miRNA-150neg/neg mice. Suppression of DTH did not occur in recipients of wild type (WT) OVA-immune
DTH-effector cells pretreated in vitro with Ts cell exosomes from tolerized miRNA-150neg/neg mice
(Figure 4A, Group C vs. A), compared to the strong inhibition by suppressive exosomes generated
from miRNA-150pos/pos wild type donors (Figure 4A, Group B vs. A). This indicated that as in the
hapten Ag CS system, DTH suppression caused by tolerization with high doses of Ag generated Ts cell
exosomes that were also dependent on their ability to deliver miRNA-150 to targeted cells.
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In the CS system, the suppressive exosomes from hapten Ag tolerized mice were additionally
activated to be able to associate with a given miRNA in vitro. Accordingly, we tested these
non-suppressive exosomes from tolerized miRNA-150neg/neg mice after incubation in vitro with
synthetic miRNA-150. These miRNA-150-treated exosomes from tolerized miRNA-150neg/neg mice
were converted to be able to suppress the adoptively transferred DTH effector cells, like the exosomes
from Ag-tolerized WT miRNA-150pos/pos mice (Figure 4A, Group D vs. A and C). Thus, the added
miRNA-150 seemed to have become associated with the initially non-inhibitory exosomes from
miRNA-150neg/neg tolerized donors to render them capable of fully suppressing adoptive transfer of
OVA-specific DTH-effector cells, to the same extent as suppressive exosomes from Ag-tolerized WT
miRNA-150pos/pos mice (Figure 4A, Group D vs. B).
As a third experimental confirmation of these findings, OVA Ts cell-derived exosomes from WT
mice, presumed to contain inhibitory miRNA-150, were pre-incubated with anti-miR-150 polynucleotide
(i.e., a chain with the reverse sequence as miRNA-150), that might hybridize with active miRNA-150.
Indeed, this led to strong reversal of the suppression mediated by these anti-miRNA-150 pulsed
OVA-induced Ts cell exosomes (Figure 4B, Group C vs. B).
Thus, considering the experiments restoring suppression in exosomes from Ag tolerized
miRNA-150neg/neg mice, there were two confirmatory results; (i): showing that initially non-suppressive
exosomes from tolerized miRNA-150neg/neg mice were reconstituted by association with miRNA-150
(Figure 4A), and (ii): showing that DTH-inhibition by natively suppressive Ts cell exosomes from
Ag high dose tolerized WT mice was abolished by association of these competent exosomes with
anti-miRNA-150 polynucleotide (Figure 4B). Therefore, these results together constituted strong
evidence that OVA Ts cell exosomes derived from OVA Ag tolerized mice mediated suppression of
DTH due to their content and likely delivery of inhibitory miRNA-150.
2.9. Non-Suppressive OVA Ag-Specific B1a Cell-Derived Exosomes from Ag-Immunized Mice Can Be Rendered
Suppressive by Association with miRNA-150
We hypothesized that in this system exosomes need two properties to be suppressive: the Ag
specificity due to surface FLC and delivery of miRNA-150. Accordingly, we tested the ability of
non-suppressive, Ag-specific B1a cell-derived exosomes from optimally immunized mice, that were
non-suppressive, likely because they contained no miRNA-150, to be rendered suppressive by similar
association with miRNA-150 (Protocol, Figure 5A). For this experiment, B1a cell-derived exosomes
were harvested from culture supernatants derived from lymph node and spleen cells of mice simply
immunized ID with OVA. They were harvested at only 2 days after ID immunization when B1a cells
produce Ag-specific IgM antibodies and Ab FLC [9,11]. The B1a cell exosomes in this supernatant
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were hypothesized to likely be OVA Ag-specific due to membrane anti-OVA BCR, and/or a surface
coating with anti-OVA Ab FLC, as shown in Figure 5B [8]. We determined that these immune B1a
cell-derived exosomes expressed CD9 and CD81 tetraspanins (Figure 5B, left). Additionally, CD9+
vesicles were found to co-express mouse kappa FLC, in contrast to samples from non-immunized
animals (Figure 5B, right top vs. bottom). Transmission electron microscopy revealed the presence of
bilamellar membranous vesicles in the pellet of ultracentrifuged supernatant of OVA-specific B1 cells
(Figure 5C). Int. J. Mol. Sci. 2020, 21, 5540 11 of 34 
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and found positive for co-expression of CD9 and antibody kappa free light chains (FLC, center,
and upper right), while some in the pellet from ultracentrifuged culture supernatant from normal
lymphoid cells expressed Ab FLC, but did not co-express CD9 (right lower). (C) B1a cell-derived
exosomes were analyzed with transmission electron microscope, showing the presence of bilamellar
vesicles. (D) Non-suppressive OVA Ag-specific B1a cell-derived exosomes become suppressive of
OVA DTH adoptive transfer when in vitro associated with miRNA-150 (Group C vs. D). (E) A dose
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Int. J. Mol. Sci. 2020, 21, 5540 11 of 33
As expected, these exosomes derived from optimally immunized, but non-tolerized donors were
non-suppressive, likely because they did not naturally contain endogenously generated miRNA-150
since they were not from tolerized mice (Figure 5D, Group C vs. B). In contrast, when these B1a
cell-derived, Ag-specific exosomes were in vitro associated with miRNA-150, they became suppressive
(Figure 5D, Group D vs. C).
In summary, these data of the OVA protein DTH system confirmed that Ag-specific, suppressive
exosomes could be actually derived either from CD8+ Ts cells, then they natively contain miRNA-150
and express surface Ag-specific FLC donated by neighboring activated B1a cells (Figure 1A, Group B),
or, alternatively, by immune B1a cells, then they natively express Ag-specific FLC and further were
associated with miRNA-150 (Figure 5D, Group D).
2.10. Dose Response of miRNA-150 Association with Immune B1a Cell-Derived Exosomes
This type of miRNA association was new, and thus required exploration of physiological relevance
by dose–response experimentation. In the CS system, this was shown to be mediated by unusually
effective, very low doses of B1a cell exosome-associating miRNA-150 [10]. Accordingly, we determined
the least dose of miRNA-150 required for switching OVA-specific B1a cell exosomes to suppressive
function in vivo. Use of decreasing serial dilutions of miRNA-150 added to exosomes from B1a cells
from early two day OVA immunized mice showed that as little as 300 ng or 10−13 moles was the
limiting dose of miRNA-150 in this system. This amount was sufficient to associate with B1a cell
exosomes to mediate highly significant suppression of adoptively transferred OVA DTH mediating
immune cells (Figure 5E, Group E vs. C).
An additional feature of this experiment was an attempt to chemically employ 5′-biotinylated
miRNA-150 for eventual testing of function of this labeled polynucleotide in suppressing the adoptive
transfer of DTH. Such a construct would be useful for detection, quantitation, and kinetic studies of the
miRNA-150 carrying suppressive B1a cell-derived exosomes. However, attempted association of the
immune activated B1a cell-derived, OVA Ag-specific exosomes with biotinylated miRNA-150—even
at the highest dose of 3 µg—was not suppressive of OVA-specific effector cells in adoptive transfer of
DTH (Figure 5E, Group G vs. C). This suggested that the native miRNA-150 (or perhaps just its native
5′ end sequence) was required for association with exosomes and/or eventual inhibition of the mRNA
targeted by miRNA-150. Therefore, this group served as an excellent miRNA control.
Overall, these studies confirmed the ability of miRNA-150 to associate with OVA Ag-specific
immune B1a cell-derived exosomes, as we found previously with this type of exosomes also from
early immune, but hapten-Ag-specific B1a cells [10]. The limiting dose here was much greater than in
the hapten system, and biotinylating the 5′ end of miRNA-150 prevented association or function in
targeted cells.
2.11. Prolonged In Vivo Suppression by Systemic Treatment of Active OVA DTH Responses with B1a
Cell-Derived Exosomes Associated with miRNA-150
Important in any therapy, is attaining a significant duration of the effect; especially in clinical
translation to patients. We showed above strong and prolonged in vivo suppression of existing OVA
DTH over four days in actively immunized mice treated with a single dose of Ts cell-derived exosomes
administered by multiple routes (Figure 3E). Accordingly, we performed a further kinetic study in
the OVA DTH system, but now employing the newly described B1a cell-derived exosomes, rendered
suppressive by in vitro association with inhibitory miRNA-150 (Figure 5D,E). We found that systemic,
single physiological-dose IP treatment begun at the 24-h peak of response with miRNA-150 associated
OVA Ag-specific B1a cell exosomes had similar profound and prolonged OVA DTH suppressive effects
over the subsequent four days (Figure 5F, red line, 50–92% suppression), when compared to identical
but miRNA-150 unassociated B1a cell-derived exosomes (Figure 5F, green line), and to hosts with
elicited active DTH that had no treatment (Figure 5F, black line). Therefore, OVA DTH suppression
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like that mediated by T cell-derived exosomes from Ag tolerized mice could be constructed from these
Ag-specific and miRNA-150 loaded B cell-derived exosomes.
2.12. Comparing the Binding of Four Different Anti-OVA mAb and Their Derived Light and Heavy Chains,
as well as Polyclonal Anti-OVA FLC to Various OVA Preparations
An important question about DTH inhibition by Ag-specific, suppressive exosomes is the
mechanism of suppression; including the mechanism of the Ag-specificity due to a coating with Ab
FLC [8]. To examine this, we employed a set of four different anti-OVA IgG monoclonal antibodies,
where each was rendered into its Ab heavy and Ab FLC. We compared the ability of these constituent
chains to whole IgG in dose response binding to native OVA Ag, adhering to wells of enzyme-linked
immunosorbent assay (ELISA) plates and serially diluted from 2.5 to 0.078 µg per ml (Figure 6A).
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Figure 6. ELISA assays to assess the ability of four different onoclonal anti-OVA Ab-derived free light
chains (FLC) to bind to native OVA, OVA tryptic eptides, and O 3- 39 eptide, as well as flow
cytometry analysis of anti-OVA Ab FLC in 2-day immune serum. (A) Binding to native OVA by serial
dilutions of four different monoclonal anti-OVA Ab-derived FLC and Ab heavy chains, vs. The whole
IgGs, shows significant binding with a particular mAb and similar strength with a given mAb and its
derived heavy and ligh chains. (B) Binding of v rious monoclonal anti-OV Ab FLC to native OVA
compared to binding of control anti-OX and anti-TNP hapten-specific mAb shows the Ag specificity of
the anti-OVA Ab FLC binding. (C) Comparison of binding of four monoclonal anti-OVA Ab-derived
FLC to either native OVA or OVA tryptic peptides, showing a difference only in the case of FLC 3.
The two-tailed Student t test, ** p < 0.01. (D) Binding of four monoclonal anti-OVA Ab-derived FLC to
OVA 323-339 antigenic determina t. (E) The presence of OVA Ag-specific Ab FLC in 2-day serum of
OVA-immunized mice (thick black line) was confirmed by flow cytometry, as compared to serum of
control non-immunized mice (thin black line). n = 3 wells or samples in each experimental repetition.
Over the dilution range employed, binding to native OVA adsorbed to plastic ELISA wells,
occurred with the whole IgGs as well as the separate Ab heavy and light chains. The anti-OVA mAb
were numbered 1, 2, 3 and 4, and a rank order of binding was determined. Binding of the isolated heavy
and light chains to native OVA Ag was in the same rank order for a given anti-OVA whole monoclonal
IgG, and just differed in strength of OVA-binding comparing the four mAb (Figure 6A). For each mAb,
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binding was best with whole IgG and next the heavy chains and least the FLC (Figure 6A), but in the
same rank order for each mAb.
Another related ELISA experiment showed that the binding to native OVA by Ab FLC was shown
to be could be Ag-specific, when compared to two different anti-hapten mAb FLC; i.e., anti-oxazolone
and anti-TNP FLC (Figure 6B). These various anti-hapten mAb FLC were shown previously to bind to
and convert non-suppressive exosomes derived by Ts cells from hapten Ag tolerized pan Ab deficient
JHneg/neg mice to suppressive function, in adoptive transfer of a CS-effector cell mixture [4].
In another ELISA assay we have compared the four mAb IgG-derived FLC for their binding
to native OVA and OVA tryptic peptides. FLC 1, 2, and 4 bound with a similar strength to both
OVA preparations, while binding of FLC 3 to OVA tryptic peptides was weaker than to native OVA
(Figure 6C). Furthermore, all assayed FLC were shown to bind to OVA 323-339 antigenic determinant
but, however, with a very low efficacy (Figure 6D).
As mentioned above, Ag-activated B1a cells provide FLC for coating of Ts cell-derived exosomes
(Figure 1C). Thus, we speculated that these B1a cell-derived FLC could be found in serum collected
from mice ID immunized with OVA 2 days earlier. Prior studies in the CS system and in a model of
early resistance to pneumococcal pneumonia indicated that such sera contain polyclonal anti-hapten
IgM Ab, and also Ab FLC with diverse Ag-specificities due to germ line V-region mutated DNA
sequences in a subpopulation of these ordinarily germ line expressing early B1a cells [14–16]. Thus,
to evaluate this idea, latex beads coated with native OVA antigen were incubated with OVA immune
sera, washed, stained against mouse kappa light chains, and subjected to flow cytometric analysis,
that revealed the presence of Ab FLC, that bound to OVA-coated beads, in tested sera (Figure 6E).
As expected, the amount of detected anti-OVA FLC was much greater in sera of OVA-immunized mice,
when compared to naive mouse sera (Figure 6E).
2.13. Testing the Anti-OVA mAb FLC That Coat Ts Cell-Derived Exosomes Reveals Their Ability to Bind to
OVA Antigenic Determinants
To assess the involvement of Ab FLC in suppression of DTH by Ts cell-derived exosomes in vivo,
the same amounts of anti-OVA FLC 1, 2, 3, and 4 were used to coat identical aliquots of Ts cell-derived
exosomes from OVA Ag tolerized JHneg/neg mice (Figure 7A, protocol). Because of their genetic defect
in Ab production, the JHneg/neg mice do not produce native Ab FLC and, therefore, their derived
exosomes are not suppressive on their own [4,8,10]. Thus, we tested the relative ability of the four
mAb-derived FLC to restore suppressive action of exosomes, when used to coat the exosomes generated
by Ts cells from OVA Ag-tolerized JHneg/neg mice. We found that the JHneg/neg mouse Ts cell exosomes
coated with FLC 2, 3, and 4 mediated significant suppression of adoptively transferred DTH effector
cells (Figure 7B). Simultaneously, we performed an ELISA-based assay to compare the binding of
JHneg/neg mouse Ts cell-derived exosomes coated with four mAb-derived FLC to native OVA and
OVA tryptic peptides (Protocol, Figure 7C, left), that was found similar in the case of FLC 1, 2, and 4
when tested as freely dispersed in assay buffer (Figure 6C). This assay showed a significantly greater
amount of JHneg/neg mouse Ts cell exosomes that bound to OVA tryptic peptides in comparison with
binding to native OVA, when these exosomes were coated with FLC 1, 2, and 4, but not with FLC 3
(Figure 7C), suggesting that some FLC bind OVA tryptic peptides stronger when coated onto exosomes.
Therefore, these observations led us to hypothesize that the ability of Ab light chains to allow exosomes
to Ag-specifically suppress DTH effector cells depends mostly on the total avidity of Ag-binding by
multiples of the FLC that coat suppressive exosomes, that combines their individual affinities. To test
this hypothesis, we have applied FLC 2 and 3, that differed in their binding capability (Figures 6C
and 7C) and suppressive activity (Figure 7B), as well as 2-day immune serum from OVA-immunized
mice, onto an affinity chromatography column filled with sepharose conjugated with OVA tryptic
peptides. The yielded column eluates containing FLC that had strongly bound to OVA tryptic peptides,
were then used to coat JHneg/neg mouse Ts cell-derived exosomes that were incubated with DTH effector
cells prior to their adoptive transfer. We observed that coating of JHneg/neg mouse Ts cell exosomes with
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OVA tryptic peptide-binding FLC 2 and 3, and OVA-immune serum FLC, led to significant suppression
of DTH response (Figure 7D). This confirmed that the ability of FLC to bind the Ag peptides indeed
determines their suppressive activity when coating the Ts cell exosomes.
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(A) Protocol: Inhibition of adoptively transferred OVA DTH effector cells when preliminarily pulsed
with exosomes from Ag-tolerize WT don rs, compared to those from similarly g tolerized JHneg/neg
mice, that in some cases were additionally coated in vitro with t e four different anti-OVA mAb FLC.
(B) Adoptive transfer of OVA DTH effector cells pulsed in vitro with OVA-specific Ts cell-derived
exosomes from A -tolerized JHneg/neg mice, reconstituted for suppression by in vitro coating with the
four different anti-OVA mAb FLC. (C) ELISA-based as ay (scheme—left) o evaluat the binding of
JHneg/neg mouse Ts cell-derived exosomes coated with four different monoclonal anti-OVA Ab FLC to
either native OVA or OVA tryptic peptides, showing the stronger binding to OVA tryptic peptides in
the case of FLC 1, 2, and 4. (D) Successful reconstitution of suppression by coating of non-suppressive
T cell exosomes derived from OVA Ag-tolerized JHneg/neg mice with anti-OVA mAb FLC numbers 2
and 3 or 2-day immune serum FLC eluted from OVA tryptic peptide-linked affinity column. (E) Use of
OVA tryptic peptides to potentially block anti-OVA mAb FLC that coat Ts cell-derived suppressive
exosomes. The OVA peptides block anti-OVA mAb FLC and FLC from OVA-immune serum that
coated Ts cell-derived suppressive exosomes from Ag-tolerized JHneg/neg mice, on adoptive transfer of
DTH, mediated by a mixture of APCs and OVA-specific DTH effector T cells. (F) ELISA-based assay
(scheme—left) to evaluate the binding of wild type mouse Ts cell-derived suppressive exosomes to
either native OVA, OVA tryptic peptides or OVA 323-339 antigenic determinant, showing that exosomes
originally coated with anti-OVA FLC can bind to all assayed OVA preparations. Results of in vivo
assays are shown as delta ± standard error (SE, n = 5 mice in each group), and of in vitro assays as
mean ± standard deviation (SD, n = 3 wells in each experimental repetition), one-way ANOVA with
post hoc RIR Tukey test or two-tailed Student’s t-test, * p < 0.05; ** p < 0.01; *** p < 0.001.
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It has been previously shown that coating of exosomes from Ts cells generated by hig Ag
dose-induced tolerance with Ab FLC mediated the Ag-specificity of suppression [4,6,8]. According to
our overall observations, we therefore proposed that Ab FLC, when coating the suppressive exosomes,
bind to antigenic peptide determinants, that can enables Ag-specifica targeting of APCs present in the
DTH effector cell mixture. To initially test this hypothesis, we coated JHneg/neg mouse Ts cell-derived
exosomes with FLC 2 and 3, and with serum-derived FLC, and then incubated these FLC-coated
exosomes with OVA tryptic peptides prior to treating DTH effector cells. Pre-incubation of the
FLC-coated exosomes with OVA tryptic peptides blocked their suppressive activity (Figure 7E, groups
D vs. C, F vs. E and H vs. G), thereby proving that the interaction of FLC-coated exosomes likely with
Ag peptides is required for suppression.
Thus, to finally confirm the ability of FLC-coated exosomes to bind to peptide antigenic
determinants, we have compared the binding of wild type C57BL/6 mouse Ts cell exosomes, that are
originally coated with Ab FLC (Figure 1C), to native OVA, OVA tryptic peptides, and OVA 323-339
antigenic determinant, in an ELISA-based assay (Protocol, Figure 7F, left). This showed that the highest
amount of the suppressive exosomes bound to OVA tryptic peptides, then to native OVA and to OVA
323-339 peptide (Figure 7F). Taking into account that only a part of the OVA-primed B1a cells produce
OVA-323-peptide-specific FLC, this observation unequivocally proved that the suppressive exosomes
bind to peptide antigenic determinants on the APC due to their coating with Ag-specific FLC, thereby
allowing antigen-specific targeting of the APCs expressing surface OVA Ag-peptide complexed with
MHC to enable suppression of the DTH response.
3. Discussion
3.1. Ag-Specific Ts Cell-Derived Exosomes Mediate Tolerance Induced by Ag High Dose
Systemic Administration
The current study has contributed greatly to further understanding of our original discovery of
Ag-specific immunosuppressive exosomes [4]. These prior findings were from the hapten-specific
effector T cell-mediated, in vivo system of cutaneous CS, where the Ag-specific tolerance was shown
to be due to exosome-like nanovesicles coated with Ab FLC delivering miRNA-150 [4,8]. The central
finding of this unique system was that systemic treatment of mice with such Ag-specific, immune
suppressive exosome-like nanovesicles strongly inhibited established CS in actively sensitized hosts,
when we systemically administered a single physiological dose of the vesicles at the 24-h peak of
the cutaneous immune response. Those inhibitory exosome-like nanovesicles in the CS system were
secreted by CD8+ Ts cells not expressing the Treg cell marker FoxP3 [4], and targeted Ag-presenting
macrophages [6]. After induction of tolerance to hapten in donor mice, their suppressive exosome-like
nanovesicles were found in their immune sera, plasma, and in the supernatant of their cultured spleen
and lymph node cells [4]. Thus, suppressive exosomes were released and acted systemically to achieve
Ag-specific immunological tolerance due to their suppression, and were able to act at local sites of CS
elicitation in the ear skin after systemic administration.
This current new study was extended to OVA protein Ag-induced tolerance, that was similarly
mediated by Ag-specific nanovesicles, determined to be common small EVs, most likely exosomes,
coated with anti-OVA Ab FLC, and also again delivering inhibitory miRNA-150, acting on macrophage
APC, likely by binding to their surface expressed OVA peptides in MHC to inhibit their companion
peptide-Ag-MHC-specific DTH effector T cells.
3.2. Development of the OVA Protein Ag-Induced DTH System Regulated by Ag-Specific, Ts Cell-Derived
Inhibitory Exosomes Delivering miRNA-150
Our findings in the hapten-induced CS system were new, unique, unconventional, and a bit
controversial. The findings were made in a system of hapten chemical Ag-specificity, and indicated
that the exosome-like nanovesicles targeted the APC, that guided the eventual suppression of their
companion CS-effector T cells [6]. However, the exact entity likely on the APC surface bound by the
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Ag-specific FLC coating these suppressive exosomes could not be determined in this CS system. This
is because hapten immunization and challenge results in hapten binding over the whole APC surface
as it becomes chemically covalently linked to diverse host proteins.
The current study was performed in the different, OVA protein Ag-induced DTH system,
and allowed expansion of the previous findings by being able to determine the Ag entity targeted
on the APC surface. This enabled exosome-mediated transfer of miRNA-150, that in turn activated
suppressive function of these APC, that then inhibited companion OVA-specific DTH-effector T
cells. Our current new findings indicate that peptides of the OVA Ag, likely in complex with MHC
on the APC surface, are very likely bound by Ab FLC coating the surface of these Ts cell-derived
suppressive exosomes.
There was a further important property of treatment with the previously studied hapten Ag-specific
exosomes, expanded here in the OVA protein Ag DTH system. In CS, in vivo suppression was mediated
by physiological doses of the nanovesicle exosomes, that was effective even when a single systemic
IP dose of suppressive exosome vesicles was administered at the in vivo maximum 24 h peak of the
cutaneous response and lasted for several days [4]. In the current study, suppression of OVA DTH was
achieved by systemic administration of a physiological dose of exosomes from OVA-tolerized mice by
the IP, IV, ID, and even the oral route; the latter producing the most powerful inhibition (Figure 3E).
3.3. Significance of Administrating the Suppressive Exosomes Orally
A remarkable new finding was that the OVA-specific suppressive exosomes can even be given
orally to actively immunized recipients in a single dose, again at the height of the T cell effector response
to achieve strong inhibition of elicited DTH. In fact, this produced the strongest effect of all routes
examined with prolonged suppression over four days of established DTH at the particular systemic
site of the Ag-challenged ear skin (Figure 3E). These findings are very important since in general they
resemble the clinical situation of treating a patient with a pre-existing and ongoing immune-mediated
reaction. Furthermore, successful and powerful suppressive treatment with exosomes via the oral
route—if translated to the clinical situation—is a low impact and high effect treatment modality that
obviously would be convenient to patients; especially children.
3.4. Hapten and Protein Ag-Specific Suppressive Exosomes
Our prior study was the first description of natural, Ag-specific exosome-like nanovesicles,
uniquely composed of components from two different cell types; i.e., T cells and B cells. The T
cell-derived component was miRNA-150 contained in exosome-like nanovesicles from hapten immune
tolerance-mediating CD3+ CD8+ Ts cells induced by administration of high systemic doses of hapten
Ag [4]. These CD8+ Ts cell-derived exosomes had Ag non-specific, suppressive activity due to their
ability to deliver inhibitory miRNA-150 to targeted cells [4]. Furthermore, anti-hapten B1a cells,
also activated by the tolerogenic procedure, provided hapten-specific Ab FLC for coating the Ts
cell-derived exosome-like nanovesicles to render them Ag-specificcally suppressive of elicited CS
responses [4,8].
In the current study, OVA Ag-induced high dose tolerance was also found to be mediated by
CD8+ CD3+ cells producing Ag-specific, suppressive exosomes, similarly coated with Ab FLC and
particularly transferring miRNA-150 cargo. Furthermore, the OVA-Ag-specific suppressive exosomes
similarly targeted the APC that were companions of the finally suppressed OVA-specific DTH effector
T cells (Figure 2C).
Other EV-mediated mechanisms of immune suppression have already been described and claimed
to have Ag-specific activity. However, this has often been tested only in one-way Ag-activity system
by simple comparison to challenge with another Ag or just media, or testing non-immune hosts with
the involved Ag, as controls. Thus, the mechanisms in these studies should instead be considered only
Ag-dependent [17–28]. Furthermore, the Ag-specificity of the function of other suppressive exosomes
was not established in the important and meticulous study of RNAs involved in the suppression of
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Th1 cells by classical FoxP3+ Treg cells [25], and in another study on immunopathogenesis mediated
by Treg cell-derived EVs [29].
In great contrast, our prior studies on CS suppression definitively established the strict hapten
Ag-specificity of exosomes by dual reciprocal testing [4,8,10]. In the current DTH studies, we have
also reciprocally tested the Ag-specificity of exosome-mediated tolerance to a pair of unrelated
protein Ag; i.e., OVA and KLH. Accordingly, OVA-specific suppressive exosomes strongly inhibited
effector DTH responses to OVA protein Ag in actively immunized mice. Reciprocally, KLH-specific
suppressive exosomes failed to suppress OVA-induced DTH (Figures 3D and 2B). This proved that
protein-Ag-specific suppressive exosomes acted in a strictly Ag-specific manner.
3.5. Protein Ag-Specific, B1a Cell-Derived, Non-Suppressive Exosomes Can Be Rendered Suppressive by In
Vitro Association with miRNA-150
A very important aspect of the hapten CS-inhibiting, Ts-cell-derived exosomes was carriage and
then delivery of miRNA-150 to targeted cells, that alone compared to controls inhibited Ag presentation
by these acceptor macrophages [6]. Importantly, we confirmed this exact scenario in OVA protein Ag
high dose tolerance induced by exosomes mediating suppression of OVA DTH, that were effective only
in the presence of Ag-presenting macrophages. In both the CS and DTH systems, Ag-specific targeting
of exosomes derived from CD8+ CD3+ Ts cells was mediated by their surface Ab FLC derived from
cells other than those that produced the exosomes (i.e., by co-activated B1a cells) [8].
Furthermore, we described another and equivalent complex biological process that was based on
the recognition that the essential aspects of the suppressive exosomes in CS and DTH was exosome
surface Ag-specificity and delivery of miRNA-150 [4,10]. To construct this with natural components,
we employed exosomes derived from B1a cells generated at only two days after immunization ID with
OVA alone [11,30]. Although these B1a cell-derived exosomes were OVA-specific due to the surface
expression of OVA Ab FLC and/or anti-OVA BCR, they were not suppressive, since they lacked a
miRNA-150 cargo, because the donors were not Ag-tolerized. Thus, of crucial significance—as in
CS suppression [10]—we found that in vitro association of these B1a cell-derived, OVA Ag-specific
exosomes with miRNA-150 alone rendered them suppressive of the OVA-specific effector T cells by
acting on their APC. Furthermore, these miRNA-150-associated, anti-OVA B1a cell-derived exosomes
were strongly suppressive over subsequent days, when injected systemically at the 24-h peak of the
OVA-specific DTH response (Figure 5F), and this was comparable to suppression mediated by the
OVA-specific Ts cell-derived exosomes (Figure 3D,E) [10]. In summary, we hold that achieving this
suppression by simply combining the naturally produced B1a cell-derived exosomes from optimally
immunized donors that express surface Ab—together with selection of carried miRNA-150 cargo—is
the strongest proof of principal definitively verifying the ideas concerning the biologically functional
Ag-specific suppressive exosomes. This was the main focus of our ongoing studies.
3.6. Dose Response Testing to Determine the Limiting Dose of Associating miRNA-150 to Mediate Suppression
of OVA DTH by B1a Cell Exosomes
The in vitro procedure of associating miRNA-150 with anti-OVA B1a cell-derived exosomes
also allowed for testing the limiting dose of associating miRNA-150 able to mediate suppression of
OVA-induced DTH. Such a rarely done dose response experiment showed that the minute dose of only
300 ng or 1 × 10−13 moles of miRNA-150 sufficed for suppression of an OVA-specific DTH effector
cell mixture adoptively transferring DTH (Figure 5E). This compares to the very unusual, ultra-low
dose of 50 × 10−15 moles, or 50 femtomoles of miRNA-150, associating with B1a cell-derived hapten
Ag-specific exosomes for suppression of CS adoptive cell transfer [10]. However, there is as yet no
method allowing accurate determination of the percentage of miRNA-150 taken up by these exosomes
and further exosome uptake by the targeted cells. Therefore, in actuality, much less miRNA-150 may
be exosome-transferred in both cases to induce the biological effects.
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The apparent difference in limiting dose of miRNA-150 in CS and DTH may be due to the
distinctive aspects of the involved mechanisms. In CS, the targeted cells are exposed to and linked with
many molecules of reactive hapten applied to these macrophage APC, and thus will likely have great
amounts of hapten covalently conjugated to multiple entities on their surface beyond those haptens
conjugating to self-peptides complexed in MHC. This would allow for great diversity of Ab-linked
suppressive exosome binding, uptake, and possible subsequent induction of intracellular mechanisms
mediated by transferred miRNA-150. In contrast, in OVA-induced DTH, similar Ab-coated suppressive
exosomes seem to just bind the foreign OVA Ag-derived peptides only expressed in complexes with
limited numbers of MHC molecules on the APC surface, as the only possible Ag-specific targets for
their surface Ab FLC.
3.7. Confirmation That Ag-Specific Exosomes Mediate miRNA Delivered Suppression in Two Different
DTH Systems
Various findings of Ab-dependent, exosome-mediated suppression in hapten CS, were now
repeated in protein Ag-induced DTH. As a first potential treatment scenario, this offered a unique
situation of constructing functionally suppressive exosomes derived again from two cell types;
i.e., T cells and B cells. Firstly, this has potential clinical significance, since there is the tolerogenic route
of inducing Ts cell-derived endogenous miRNA-containing exosomes to be coated by either native or
chosen B1a cell-derived, endogenously available Ab FLC.
In a second scenario, aimed at creating suppressive B cell-derived exosomes for treatment,
immunization of patients with exogenous Ag or altered self-Ag might induce a B1a cell source of
exosomes that are Ag-specific due to either a surface expression of BCR specific for that immunizing Ag,
or via a coating of endogenous Ab FLC. Additionally, two exosome types—i.e., Ts cell- or B1 cell-derived,
that could be, respectively, endogenously or in vitro associated with a chosen miRNA, or likely
siRNA—would then mediate selected miRNA-dependent Ag-specific alteration of APC function.
Indeed, when transferred to totally syngeneic recipients (Figures 3E and 5E), they may induce desired
epigenetic alterations in specifically targeted host APC, that bear Ag-peptide surface determinants of
the given Ag to be bound by the Ab FLC or Ab-like BCR on the exosome surface. The in vitro miRNA
association process would follow steps in the new alternate pathway for in vivo exosome-mediated
transfer of extracellular RNA (exRNA) between cells that we described previously [10]. Clinically, there
are other conditions possibly applicable to regulation by the Ag-specific chosen miRNA-delivering
exosomes, involving protein Ag DTH-like systems; possibly including protein immune reactivity in
asthma, autoimmunity, transplantation, or cancer. Since exosomes seem to be universal nanoparticles
of all of life, such natural nano particle constructs would constitute a new simple approach for
simultaneous and mutually interacting chosen Ag and gene-specific therapy to curb excessive DTH or
related T cell reactivity in such disease processes.
3.8. Potential Application of Dual Ag- and Gene-Specific Exosome to Clinical Conditions Like
Anti-Cancer Therapies
Similar combined specific treatment of leukemia and cancers is becoming available in emerging
chimeric T cell antigen receptor (CAR) therapy. This might be delivered instead by exosomes with
advantages as cell-free carriers, a far less complicated modality for targeted therapy in cancers and
possibly in other diseases [31]. However, current CAR therapy is dependent on a single V-region
gene encoded T cell reactivity to a single given peptide-Ag/MHC determinant. Unfortunately, this
fixed property is subjected to the well-known ability of cancers to evolve resistance to a given
therapy, in this case away from the vulnerable single tumor expressed monoclonal T cell receptor for
Ag-peptide/MHC [32–34]. This compares to the possibility of using exosomes coated with easily rotated
Ab of differing specificity and also to the dual possibility to use readily selected, different therapeutic
miRNA or siRNA. Together, this achieves varying Ag or oncogene specific exosome-mediated therapy,
that would be much less prone to tumor escape.
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Furthermore, in a variety of cancers, treatment with anti-PD-1 or anti-PD-L1 Ab, or other analogous
negative co-stimulation specific Ab, that often is incomplete when used as Ab alone, could be used as
an exosome coating for check point targeting to reverse tumor mediated suppression of host effector T
cell anti-tumor reactivity. When armed with multiple check point-targeting mAb, such therapeutic,
Ag-specific exosomes might not only cover multiple target check points, making tumor escape less likely,
but also could simultaneously deliver relevant inhibitory RNAs to disable the pro-oncogenetic function
of involved suppressive cells [35]. Accordingly, exosomes could be constructed to inhibit cancer
cell-induced immunosuppression by both, specific anti-PD1/L1 Ab coating and delivery of engineered
hybridizing gene sequences encoded by selected DNA or RNA, or instead for CRISPR/cas−9 oncogene
targeting [36]. Additionally, for these various scenarios of dual Ag and gene specific exosome-mediated
anti-cancer therapies, the prospect of efficacious oral therapy would undoubtedly have greater patient
acceptance and comfort, especially when combined with existing drug and radiotherapy that might be
reduced to achieve less toxicity in the patients.
3.9. Ab FLC Surface Binding Is Associated with ‘Activated’ Exosomes
A unique feature of both, the hapten-Ag and OVA protein-Ag systems, is that the generated
exosomes are able to bind selected Ag-specific Ab FLC and associate with chosen miRNA-150.
These unusual binding and associating features uniquely provide both highly Ag-specific binding
to targeted cells and ability to transfer gene directed, functional alterations; such as epigenetic
changes. Such dual-specific targeting, in part resulting from cargo transfer, is a unique property of the
exosome subpopulation we have described, as no other laboratories have yet reported these combined
properties. In contrast, when exosomes are similarly prepared from normal, unmanipulated animals,
they do not have either ability to be significantly coated with Ab FLC nor miRNA-150 associating
properties compared to those from animals stimulated by diverse modes of positive immunization or
immune tolerization.
We refer to these exosomes having the combined Ab FLC binding and miRNA associating
properties as ‘activated’ exosomes, as they are preferentially derived from activated lymphoid cells of
immunized or tolerized mice, and not unmanipulated normal donors [4,10]. It is currently not known
what steps in immunization or tolerization induce these activation properties, nor what are the stimuli
that produce these changes, that are not found on exosomes from non-immune donors. Acquisition
of activation characteristics is true for exosomes of mice undergoing strong and prolonged exposure
to high doses of Ag in tolerogenesis, or even mere two day ID immunization with proteins without
an adjuvant, and to exosomes from various Ag high dose-tolerized Ab-deficient or miRNA KO mice
as well.
The association of the mAb FLC with the exosome surface was determined by the ability of mAb
FLC to bind the surface of ‘activated’, but not normal, exosomes. This was verified by cytometric
visualization of FLC on the exosome surface (Figures 1C and 5B) [4,8]. Such surface and other
activations seemed to account for acquisition of both, the ability to bind specific Ag via surface Ab FLC,
that enabled mediation of Ag-specific suppressive function, and also to associate and then transfer
selected miRNA for alteration of intracellular functional effects.
This Ag-specificity was demonstrated by OVA Ag-affinity column separation of the total
suppressive exosome population that yielded two subpopulations (Figure 2A) [4]. These were
specifically Ag-binding, Ab-coated, therefore considered ‘activated’, small exosomes that had the
suppressive functional activity vs. Ag-non-binding and functionally inactive exosomes (Figure 2A).
This suggested that, in this case, employing Ag-affinity column separation suggested that only around
10% or less of the total exosomes from immunized or tolerized animals are actually ‘activated’ and able
to bind the Ag [4], or express the involved CD9 tetraspanin.
Prior studies with mast cells originally determined binding of Ab FLC to the cell membrane, that,
as shown here, also apply to the surface of ‘activated’ exosomes. The binding of Ab FLC to the mast
cell surface enabled subsequent binding of specific Ag [37]. This allowed for induction of mast cell
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degranulation and mediator release [37,38], and correlated with the activity of mast cells in several
models of immunological diseases [39]. Another connected and also unusual property of the ‘activated’
exosomes was that there was no bioactive exosome surface binding of Ab free heavy chains, nor whole
Ag-specific IgG of the same Ab source, despite their ability to bind the Ab FLC [4]. This was also true
for the mast cell binding [37,38].
3.10. Possible Role of Membrane Lipids in EV Surface Activation
We have formed the hypothesis that these properties of exosome activation are due to an increased
content of components in their membranes. This idea is based on our unpublished findings that these
vesicles have greater size (150–225 nm) than the typical exosome-like nanovesicles (50–120 nm), and by
flow cytometry showing that they can have lower expression of routine molecules present on the
surface of most exosomes, like MHC class I (unpublished). This suggests that there has been a filling in
of an expanded surface with membrane components, that we believe are likely lipids. This would be
the most immediately manipulatable surface component during exosome donor cell stimulation [40].
Furthermore, study of cellular uptake of exosomes showed that interactions with targeted cells can be
modified by changing the lipid composition of their membranes [41,42].
Concerning membrane lipids and Ab FLC binding, our ideas also came from studies showing that
binding of immunoglobulin FLC to human mononuclear cell subsets depends on surface lipids [43–45].
These ideas were sustained by our preliminary unpublished studies examining lipid binding of FLC.
Firstly, mAb FLC were shown to have stronger binding ability to certain individual lipid components,
such a phosphoethanolamine. This was determined firstly with an ELISA-type assay of lipids adsorbed
on plastic wells and then bound by mAb FLC, quantitated by a second binding with anti-light chain
mAb linked with enzyme and detected enzymatically. Secondly, liposomes constructed at small
EV size and dominantly composed of the best individual lipid binders, like phosphoethanolamine,
and less of poor Ab FLC binders like sphingomyelin, were able to bind the Ab FLC, as detected by
western blotting. Thirdly, these Ab FLC-associated liposomes had biological properties that routinely
composed liposomes did not have (Hutchinson and Askenase, unpublished data).
Studies are underway to similarly examine miRNA interactions with activated vs. normal
exosomes. The amounts of miRNA involved in association with ‘activated’ OVA suppressive exosomes
are likely minute, as we showed before in CS [10], and here in DTH (Figure 5E). It was hoped
that biotinylation of miRNA-150 would be helpful for such analysis, since it could aid detection
of the binding of miRNA to the exosome surface or associated within the ‘activated’ exosomes
by pull-down techniques [46]. Unfortunately, this biotinylation caused inactivation of miRNA-150
biological properties (Figure 5E, Group G); as predicted in the literature [47].
3.11. Similar ‘Activated’ Exosomes May Mediate RNA Transfers in Other Systems
Lipid changes of ‘activated’ exosome membranes may account for their other exceptional exosoe
subpopulation properties, like our unique finding that oral systemic suppressive therapy with
Ag-specific exosomes can affect a strong local immune reaction at a specific cutaneous anatomical site.
This may relate to the physiologically transferred functions of numerous exosomes particularly
contained in mothers’ milk and delivered to neonates [48–50]. The special property of these
exosomes is resistance to harsh conditions in the neonatal stomach, like very low pH plus digestive
enzymes [51,52], that also could be properties of ‘activated’ exosomes in the immunological systems
we described [53]. RNA cargo of milk exosomes may transfer epigenetic information to neonates
after intestinal absorption [54,55], perhaps via intestinal epithelial cell endocytosis [56,57], benefitting
the neonatal intestine [58,59], and allowing postulated subsequent systemic transfer [60], that may
influence neonatal immunity [48,49,61–64], bone formation [65,66], and development of the nervous
and endocrine systems in the neonates. However, there are as yet few studies actually showing
beneficial systemic effects in neonates of orally-delivered milk EV-carried miRNAs, and there is
some contrary data [67]. Thus, our findings of systemic oral exosome transfer of miRNA mediated
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immune suppression strengthens the idea that milk exosomes might orally transfer systemic effects to
the neonates.
Of further great relevance, there are numerous claims that among miRNAs taken orally in
foods, in some cases these mixtures contain exosomes that also can pass stomach digestion for
uptake systemically to affect host functional processes [68–70]. Again, there is controversy with
some compelling data against this concept [67,71–74]. Note, however, that these are complex issues
with many technical barriers to be overcome for definitive determinations before these issues can
be settled [75–78]. Herein however, oral treatment with claimed ‘activated’ subsets of exosomes
carrying miRNA-150 in our non-dietary system clearly showed strong and prolonged in vivo immune
suppression at a particular systemic skin site. Thus, suppressive effects of orally administered,
Ts cell-derived, Ag-specific exosomes (Figure 3E), delivering a particular inhibitory miRNA-150, favor
the idea of transferred functionality of dietary food miRNAs, under some circumstances.
Recently, casein-specific Ts cell-derived exosomes have been shown to suppress casein-induced
DTH in actively immunized mice when delivered per os in a system aimed at study of milk allergy [79].
This implies that biological functionality after oral administration is a general feature of Ts cell-derived
exosomes. One can speculate that these suppressive exosomes are firstly endocytosed by intestinl
epithelial or vascular endothelial cells in the small intestine and then transmitted to circulation,
as observed in the case of cow’s milk exosomes [56,60]. Otherwise, they may be transmitted to mucosal
lymphatic tissue to induce Treg lymphocytes. However, this aspect requires much further investigation.
3.12. Demonstration That Ag-Derived Peptides Are the Binding Targets of FLC on Ag-Specific
Suppressive Exosomes
Our prior study in the CS hapten-system showed that macrophage APC, and not the finally
suppressed effector T cells, were the direct target of the Ag-specific suppressive exosomes [6].
We hypothesized that Ab FLC on the surface of the inhibitory exosomes bound to Ag peptides in MHC
complexes on the APC surface to lead to eventual suppression by the miRNA-150-influenced APC of
the effector T cells that mediate CS [30].
Our success in generation of OVA protein Ag-specific suppressive exosomes made testing of these
ideas possible. Firstly, we showed binding of Ts cell-derived exosomes to OVA-coupled Sepharose on
an Ag-affinity column only by the effectively suppressive minor exosome subpopulation (Figure 2A),
and to an anti-CD9-coupled Ab-affinity column (Figure 1F), that strongly support our hypotheses.
In addition, cytometric analysis revealed the co-expression of CD9 and Ab FLC by exosomes from
both Ts and B1a cells (Figures 1C and 5B). To further extend these findings, we set up an ELISA
with native OVA absorbed on plastic wells, and determined the binding of four different anti-OVA
mAb rendered into FLC, as well as the isolated heavy chains, compared to whole anti-OVA IgGs.
We found that binding of OVA by IgG was the strongest, heavy chains next and FLC last, but definitely
detectable (Figure 6A,B). Comparing the four mAb, there was a consistent hierarchy of binding for all
chains and the whole IgG among each mAb type. Thus, binding native OVA by each mAb and its
chains was different; ranging from excellent to much less in some, and to nil or nearly nil in others
(Figure 6). The similar binding within a mAb IgG and its heavy and light chains likely was due
to identical immunoglobulin V-region DNA sequence mutations in the producing B cells, and thus
identical specificity of the translated mAb. Conversely, the different binding between the four mAb
likely was due to different V-region mutations resulting in different derived mAb affinities for native
OVA Ag determinants adsorbed on plastic.
Knowing that Ag-presenting macrophages were the target of the Ab FLC on the exosomes for
mediating the final Ts cell suppression of the effector T cells [4,6], we further tested suppression by the
four mAb FLC separately coating the same exosomes from Ag-tolerized, Ab-deficient JHneg/neg mice,
that gave a remarkable result. We observed a very different hierarchy in the strength of mAb dependent
exosome-mediated suppression (Figure 7B) compared to binding of native OVA (Figure 6A,B). This
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was consistent with the idea that the Ab FLC on the suppressive exosomes bound to Ag-peptides on
the APC and not to native OVA.
To investigate this further, we made a tryptic digested peptide mixture from native OVA and
tested its ability to block suppression mediated by these exosomes, using different protocols. In the
first experiments, the OVA peptides were incubated in vitro with the exosomes coated with two
different anti-OVA mAb FLC that had mediated intermediate strength exosome suppression. In both
cases we found strong reversal of suppression, when FLC-coated exosomes were blocked by OVA
tryptic peptides (Figure 7E). Additionally, from past studies, we knew that the two day sera of
OVA-immunized mice contain both anti-OVA IgM and also Ab FLC, derived from activated B1a
cells [9,16,80]. Therefore, we also coated JHneg/neg mouse Ts cell-derived exosomes with this sera,
presumably containing polyclonal immune anti-OVA Ab FLC (Figure 6E), that in fact produced strong
suppression (Figure 7D). Inhibitory blocking of suppression by these polyclonal Ab FLC with OVA
tryptic peptides resulted in the best reversal of suppression (Figure 7E, Groups G and H); likely due to
the polyclonal nature of the serum Ab vs. The mAb FLC. This overall result contributed significant
evidence suggesting that Ab FLC coating the Ag-specific exosomes bound to OVA Ag peptides on the
APC surface. This would confer the Ag-specificity of Ts cell-mediated immune tolerance [8]. We have
recently reported that, in the particular circumstances, self-tolerant exosomes can be redirected toward
suppression of allergen-induced DTH responses by coating with allergen-specific Ab FLC [81].
In a second protocol, the OVA peptide mixture was used to construct peptide Ag-affinity columns.
Passage of the Ab FLC down this column enabled testing those that actually had bound peptide
on the column in the Ag-specific exosome-mediated suppression of DTH. The same two mAb FLC,
intermediately active when coating exosomes for Ag-specific suppression, and serum polyclonal
anti-OVA Ab FLC, were applied to OVA peptide columns. The OVA peptide binding Ab FLC fractions
were eluted from each column and then used to coat exosomes from Ag tolerized JHneg/neg mice in the
suppression assay. These eluted FLC, that had bound the peptide mixture, when subsequently coating
these exosomes, led to strong suppression of DTH (Figure 7D). This result confirmed that those Ab FLC
that can bind peptides on the column, may mediate the Ag-specificity of the suppressive exosomes
(Figure 7D, Groups C, D, and E) [8].
This unanticipated result can be seen as further evidence that the binding of the anti-OVA Ab FLC
on the suppressive exosomes is likely to OVA peptides complexed in MHC on the APC surface. Thus,
an explanation may be due to the manner of binding peptides by Ab FLC in the ELISA compared to FLC
on the exosome surface that bind peptides in MHC. In the ELISA, there is only binding of low-affinity,
isolated Ab FLC dispersed in solution to the peptides adsorbed on the artificial plastic surfaces in
non-physiological conformations. In comparison, the in vivo measured, Ag-specific exosome-mediated
suppression depends on FLC that are not free but linked to the exosome surface. Here, the mAb FLC
are not dispersed but in multiples closely together on the exosome surface, turning a series of low
affinity bindings into far greater avidity for binding Ag determinant of physiological conformation
when complexed with MHC, which was confirmed in vitro in ELISA-based assay (Figure 7F). However,
more direct study of mAb FLC binding to the peptide-MHC complex will be needed to prove this point
in vivo.
3.13. Characteristics of Ts Cell-Derived Exosomes
The current study revealed that OVA-induced DTH effector cells are suppressed by Ts cell-derived
EVs of a small size (around 150 nm). These bilamellar vesicles are strongly positive for CD9 and
CD81 tetraspanins but weakly express CD63 marker (Figure 1). Additionally, our previous reports
demonstrated that the buoyant fraction of Ts cell-derived EVs is responsible for the observed suppressive
activity [4,81]. They are concentrated by ultracentrifugation from the cell culture supernatant earlier
deprived of cellular debris and filtered down to 0.22 µm [82]. Thus, the light small EV subpopulation
were called exosomes. However, it should be stressed that each cell produces very heterogeneous
populations of EVs differing in size and origin [13]. Specific subtypes of small EVs can be classified
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according to displayed pattern of markers, including variability in tetraspanin expression [82]. Besides,
the complexity of EVs makes that yielded subpopulations of EVs vary across the methods used for
their purification prior to functional studies. Thus, more detailed characteristics of Ts cell-derived
exosomes remains a subject of our further investigation.
3.14. Summary of the New Findings of Biological and Clinical Significance of the Ag- and miRNA-Specific
Exosomes That Suppress OVA Protein-Induced DTH
New findings brought by our current studies could be summarized into several main points.
(i) Uniquely, suppressive function depends on exosomes consisting of components from two
lymphocyte types (T and B cells). (ii) Ag-specificity in DTH suppression is due to exosome surface
coating with anti-OVA Ab FLC. (iii) This Ag-specificity was definitively demonstrated by reciprocal
functional suppression testing of two distinct protein-specific suppressive exosomes. (iv) Also, there
was definitive demonstration that T or B cell exosome-mediated suppression in DTH is mediated
by delivered inhibitory miRNA-150. (v) Systemic suppression of DTH could be achieved in vivo by
administration of single physiological doses of exosomes; remarkably including oral administration.
(vi) Strong, systemic suppression of maximal in vivo DTH responses at a given peripheral tissue site
was observed over several days after administration of a single physiological dose of Ab FLC coated
and miRNa-150 delivering exosomes. (vii) Exosomes suppressing DTH could be constructed with
chosen dual Ag-specific targeting and the transfer of selected miRNA-encoded epigenetic functional
effects by mixing and matching chosen surface Ab FLC and selected miRNA. (viii) These exosomes
mediated suppression by very low miRNA-150 associating doses. (ix) Determination that the Ab FLC
coating the suppressive exosomes likely binds OVA peptides that are complexed in MHC on the APC
surface was shown firstly by comparing in vitro binding of the Ab FLC to OVA, compared to strength
of suppression when coating exosomes from Ag-tolerized, Ab-deficient JHneg/neg mice; and secondly
by different peptide inhibition protocols.
To summarize, Ag-specific, Ab FLC-dependent, ‘activated’ exosome delivery of suppressive
miRNA-150 via targeted binding of Ag-peptides in MHC on APC provides a new mechanism of
immune regulation with great clinical significance, since it employs natural physiological exosomes that
can be given orally and fashioned for both chosen Ag-specific targeting and selected miRNA-specific
functional alterations of targeted cells that can last for several days.
4. Materials and Methods
4.1. Mice
Nine to 10-week-old CBA/J, BALB/c, JH knock out (JHneg/neg), C57BL/6 or miRNA-150 knock out
(miRNA-150neg/neg) male mice from Jackson Laboratories (Bar Harbor, ME, USA) or CBA mice from the
Breeding Unit of the Jagiellonian University Medical College, Faculty of Medicine (Krakow, Poland)
were fed autoclaved food and water ad libitum. All experiments were performed according to the
guidelines of Ethics Committees of Yale (approval no. 07381) and Jagiellonian (approval no. 122/2013
and 88/2017) Universities.
4.2. Antigens, Reagents, and Culture Media
The following reagents were used: ovalbumin (OVA), serum-free Mishell–Dutton medium,
RPMI−1640, minimal essential medium with amino acids, HEPES, 2-mercaptoethanol (Sigma-Aldrich,
St Louis, MO, USA), keyhole limpet hemocyanin (KLH, Stellar Biotechnologies, Port Hueneme,
CA, USA), Dulbecco’s phosphate-buffered saline (DPBS), penicillin/streptomycin, sodium pyruvate,
L-glutamine (Gibco Life Technologies, Grand Island, NY), acetone, ethanol, glucose (P.O.Ch.,
Gliwice, Poland), EDC (1-ethyl−3-(3-dimethylaminopropyl)-carbodiamide, Pierce, Thermo Fisher
Scientific, Waltham, MA, USA), EDTA (BDH, Poole, UK), extra virgin olive oil (Basso Fedelee Figli,
San Michele di Serino, Italy).
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4.3. Generation of Ts cell-Derived, Protein Ag-Specific, Suppressive Exosomes
Ts cells from OVA Ag-tolerized mice releasing suppressive exosomes were induced in an analogous
manner to the tolerogenic procedures described in CS [4]. Thus, mice were injected IV on days 0 and 4
with 0.2 mL of a freshly prepared 10% DPBS suspension of syngeneic erythrocytes conjugated with
OVA or, in some instances, with KLH protein Ag. We determined in preliminary experiments that
EDC is an efficient activating agent for the coupling of protein Ag to erythrocyte membrane proteins.
For full tolerogenesis, these IV treatments were followed by intradermal (ID) immunization on two
consecutive days 8 and 9 with a total of 0.2 mL of a 0.5 mg/mL OVA each time (100 µg, injected into
four sites in the abdominal areas at 25 µg per site), or similarly KLH, both used as a 0.9% NaCl-solution
and without adjuvant. After lymph node and spleen collection on day 11, single cell suspensions were
cultured at 37 ◦C in protein-free Mishell-Dutton medium at a concentration of 2 × 107 cells/mL for 48 h.
To enrich exosomes, the resulting culture supernatant was subsequently centrifuged at 300× g and then
3000× g for 10 min, then filtered through 0.45- and then 0.22-micrometer molecular filters (Miltenyi
Biotec, Waltham, MA, USA) and finally ultracentrifuged twice at 100,000× g for 70 min at 4 ◦C [4].
The resulting pellet was resuspended in DPBS and used as OVA Ag-specific (or KLH Ag-specific)
exosomes [4]. This pellet containing OVA-specific Ts cell-derived exosomes was absorbed onto copper
grids and negatively stained with 3% uranyl acetate, and then visualized under transmission electron
microscope (JEOL JEM2100, Tokyo, Japan). Furthermore, it was subjected to nanoparticle tracking
analysis (NTA, Nanosight, Malvern, UK) [4].
In some instances prior to culture, mouse lymph node and spleen cells from Ag-tolerized donors,
were depleted of either CD3+ or CD8+ cells by incubation with, respectively, anti-CD3 or anti-CD8
monoclonal IgG antibodies, and rabbit complement for 60 min in 37 ◦C water-bath. Afterwards, dead
cells were removed by discontinuous gradient centrifugation on Ficoll (1.077 g/mL, GE Healthcare,
Chicago, IL, USA).
In some experiments, actively tolerized mice were ear challenged on day 11, and subsequent
ear swelling responses were measured as described below. In some instances, tolerized and actively
immunized mice were depleted of clodronate-sensitive cells (i.e., macrophages) by IP injection of
0.2 mL of clodronate liposomes (Department of Molecular Cell Biology, Vrije University, Amsterdam,
the Netherlands) in PBS, at 24 h before ear challenge [6].
4.4. In Vivo Treatment of Mice Actively Immunized with OVA with Suppressive Exosomes Injected at the Peak
of DTH Response
Mice were immunized ID with a total of 100 µg of OVA, as described above, and 5 days later DTH
ear swelling was elicited by ID injection of 10 µL of OVA 0.9% NaCl solution (0.5 mg/mL, thus 5 µg per
ear) into both ears. The pellet containing OVA Ag- or KLH Ag-specific suppressive exosomes was
used for treatment of the mice actively ID immunized for elicitation of OVA-specific DTH either at
immunization, or just before ear challenge or at the peak of the response 24 h after ear challenge with
OVA Ag, at a dose of 1 × 1010 EVs per mouse [11]. These mice were systemically IP injected with
the DPBS suspension of exosomes at a dose of about 1 × 1010 nanovesicles per recipient. This model
allowed testing of Ag-specificity of exosome action. Subsequent ear thickness was measured with an
engineer’s micrometer daily up to 120 h after challenge by a blinded observer [4,12].
To calculate the increase in ear thickness indicating strength of DTH, values of background ear
thickness, measured before ear challenge, were subtracted from values of ear thickness at particular
time points after ear challenge. Furthermore, to evaluate the net swelling response, mean ear thickness
increase in non-immunized but similarly OVA Ag challenged littermate control mice was subtracted
from the ear thickness increase measured in each ear of mouse of each control or experimental group.
In general, groups consisted of 5 mice and experiments were repeated 2–4 times. The average ear
swelling was expressed as the delta ± standard error (SE), after subtraction of the negative control
value. The two-tailed Student t-test or one-way analysis of variance (ANOVA) with post hoc RIR
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Tukey test were used to assess the significance of differences between groups, with p values of less
than 0.05 taken as the minimum level of statistical significance.
Exosome counts were estimated by nanoparticle tracking analysis (Nanosite, Malvern, UK).
The dose used for treatment of actively immunized mice was considered physiological, since this is the
average number of exosomes per ml of blood in normal unmanipulated mice.
Where indicated, exosomes either derived from cultures of Ts-cells or derived from early two day
OVA immune B1 a cell-derived supernatants and then associated in vitro with inhibitory miRNA-150,
were systemically administered, at the same doses, but in different volumes of DPBS (0.2–0.5 mL),
directly to actively immunized mice via IV, IP, or ID routes. Furthermore and most importantly,
the same suppressive exosomes at the same dose were also administered orally (per os, PO) using a
gastric feeding tube. For all of the compared systemic exosome treatments, suppressive and control
exosomes were administered just after measurement of the 24-h peak of active ear swelling response.
In the case of PO delivery of the exosomes, mice were kept fasting for 2 h before and 1 h after
administration of the suppressive exosomes.
4.5. In Vitro Treatment of OVA DTH Effector Cell Mixture with Exosomes, Prior to Their Adoptive Transfer to
Naive Recipients
OVA DTH-effector cells were obtained from mixed spleen and lymph node cells of mice actively
sensitized by ID multiple injections of a total of 100 µg OVA in plain 0.9% NaCl (as described above) and
harvested at day 4 after immunization [4,11]. OVA Ag-specific Ts-cell-derived, suppressive exosomes
were used at the same dose of 1 × 1010 EVs for in vitro pulsing of a mixture of DTH-effector T cells
and APC, at 7 × 107 total lymphoid cells to be transferred per eventual recipient. Then, the exosome
pulsed DTH effector cells were adoptively transferred into naive recipients, in which 24 h later DTH ear
swelling responses were elicited by ID injection of 10 µL of OVA 0.9% NaCl solution (0.5 mg/mL, thus
5 µg per ear). Ears were measured for thickness with an engineer’s micrometer (Mitutoyo, Kawasaki,
Japan), at 24 h after challenge. Results were statistically analyzed as described above.
4.6. Polyribonucleotide Treatments to Induce Suppressive Activity of Non-Suppressive Exosomes, or to Block
Their Suppressive Activity, Prior to Incubation with DTH Effector Cell Mixture
In some instances, Ts-cell-derived, OVA-specific exosomes were pretreated with a polynucleotide
antagonist of miRNA-150 (anti-miRNA-150, Dharmacon, Lafayette, CO, USA), at a dose of 3 µg
per total exosomes (1010) per each of eventual five recipients of exosome-pulsed DTH-effector cells
(7 × 107, the average number of cells transferred IV to each recipient). After washing away of unbound
anti-miR-150 molecules by ultracentrifugation, the mixture of DTH effector cells and miRNA antagonist
associated exosomes were incubated in a 37 ◦C water bath for 30 min. Then, the exosome treated and
control DTH effector cells were adoptively transferred into naive recipients, as described above.
In other experiments, exosomes from Ag-tolerized miRNA-150 neg/neg mice were treated in a
37 ◦C water-bath for 30 min with synthetic miRNA-150 in a dose of 3 µg per 1010 exosomes to be
used subsequently to treat the DTH-effector cell mixture (7 × 107), per single eventual recipient. Then,
through ultracentrifugation, we removed excessive, exosome-non-associated miRNA-150 molecules
and used the resulting miRNA-150 pulsed exosomes to treat the DTH effector cells in vitro prior to
washing away the exosomes and then IV adoptive transfer of the cells.
4.7. Ab FLC Coating, OVA Peptide Blocking, and OVA Ag or Anti-CD9 Affinity Column Chromatography of
Ts-Cell-Derived Exosomes
Ts cell-derived exosomes from Ag tolerized JHneg/neg mice were non-suppressive due to the lack
of surface FLC, but nonetheless carried miRNA-150. These were converted for Ag-specific suppression
by surface coating with various anti-OVA FLC (derived from either four different monoclonal Ab or
immune serum of 2 day OVA-immunized mice) by incubation overnight on ice. This was followed by
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ultracentrifugation at 100,000× g to remove unbound FLC into the supernatant from the Ab FLC-coated
exosomes in the pellet.
In other instances, OVA-specific Ts cell-derived exosomes endogenously coated with B1 a
cell-derived Ab FLC, were initially blocked with tryptic digested OVA peptides by a preliminary
2-h incubation in 37 ◦C water-bath. This was followed by ultracentrifugation to remove excessive
OVA peptides into the supernatant from peptide-blocked exosomes in the pellet. In yet other cases,
these OVA-specific, Ts-cell-derived exosomes were separated by affinity chromatography on columns
filled with Sepharose coupled with either native OVA Ag or with purified anti-CD9 monoclonal
antibodies [4].
4.8. Generation of B1 a Cell-Derived Exosomes and Their In Vitro Association with miRNA-150
To induce very early activated Ag-specific B1 a cells, mice were immunized with OVA protein Ag
by ID injections of total volume of 0.2 mL for four separate simultaneous intradermal injections of a
0.5 mg/mL OVA solution in 0.9% NaCl (total ID immunizing dose of 100 µg OVA) without adjuvants
on days 0 and 1 [11]. Then, on day 3, lymph nodes and spleens containing the immune B1 a cells
were collected and single cell suspensions were cultured in protein-free Mishell-Dutton medium at
a concentration of 2 × 107 cells/mL for 48 h [9]. The resulting culture supernatant was subsequently
centrifuged at 300× g and then 3000× g for 10 min, filtered through 0.45- and then 0.22-micrometer
molecular filters and then ultracentrifuged twice at 100,000× g for 70 min at 4 ◦C. The pellet presumably
containing B1 a cell-derived exosomes was absorbed onto copper grids and negatively stained with
osmium tetroxide, and then visualized under transmission electron microscope (FEI Tecnai T12, LaB6,
Thermo Fisher Scientific, Waltham, MA, USA).
The resulting pellet containing enriched Ag-specific B1 a cell-derived exosomes was resuspended in
DPBS. Then, where indicated, the Ag-specific B1 a cell-derived, non-suppressive exosomes that received
no endogenous miRNA-150, since they were from immunized and not tolerized mice, were associated
in vitro with synthetic miRNA-150. This was achieved by incubation in 37 ◦C water-bath for 30 min
with miRNA-150 at a dose of 3µg per 1010 nanovesicles. These exogenously miRNA-150-associated
exosomes were subsequently used to pulse 7 × 107 DTH-effector cells per single recipient. Prior to
incubation with the DTH-effector cells, the Ag-specific, B1 a cell-derived exosomes that had been
incubated with free miRNA-150 for association, were washed by a single ultracentrifugation to remove
excessive, exosome-non-associated miRNA-150 molecules.
4.9. Cytometric Analysis of Exosomes and Evaluating the Presence of Antibody Light Chains in Two-Day
Serum of OVA-Immunized Mice
Aldehyde/sulphate latex beads (4 µm, Life Technologies, Thermo-Fisher Scientific, Carlsbad, CA,
USA) were incubated in DPBS with OVA-specific exosomes derived from Ts cells or B1 a cells at
room temperature for 2 h with gentle agitation. Afterwards, exosome-coated beads were blocked
with 100 mM glycine, washed, resuspended in DPBS, and stained with fluorescein isothiocyanate
(FITC)-conjugated mAb against mouse kappa light chains (BD Biosciences, San Diego, CA, USA) and/or
phycoerythrin (PE)-conjugated mAb against mouse CD9, CD63 or CD81 tetraspanins (BD Biosciences,
San Diego, CA, USA). Alternatively, the aldehyde/sulphate latex beads were coated with native OVA
Ag by overnight incubation at 4 ◦C with gentle agitation, and then, after washing, were incubated with
2 day immune serum from the ID OVA-immunized mice. After washing, these OVA-coupled beads
were stained against mouse antibody kappa light chains to evaluate the eventual presence of anti-OVA
FLC in the serum.
4.10. ELISA for Assessment of Binding to Native OVA, OVA Tryptic Peptides, or OVA 323-339 Peptide by
Various Anti-OVA mAb FLC
Isolated OVA-specific mAb FLC and isolated mAb free heavy chains were made from four different
OVA-specific mAb IgGs (clones F2 3.58, 7 E9.17, 7 H7.E1, and 11 B.1) from the Frank Fitch collection,
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University of Chicago, that were kindly provided by Anne Sperling. The whole IgGs were reduced
and alkylated to separate heavy and light chains in the laboratory of Frank Redegeld at the University
of Utrecht, the Netherlands. Proteins were eluted from columns with 6 M guanidine and subsequently
loaded onto a gel filtration column (HiLoad 16/60 Superdex 200 pg, GE Healthcare, Chicago, IL, USA)
to separate anti-OVA mAb heavy and light chains (FLC). Subsequently, samples were dialyzed versus
PBS to remove guanidine and then concentrated.
Then, OVA Ag-specific mAb FLC, heavy chains, and whole IgGs were added to quadruplicate
microwells of high binding ELISA plates that previously were coated with native OVA (25 µg/mL).
After Ag coating, the plates were blocked with PBS/10% FBS/0.05% Tween-20 for 1 h at room temperature,
washed and finally incubated with the four separate OVA-Ag-specific Ab FLC, heavy chains, or whole
IgG1, all diluted in PBS/1%FBS/0.05% Tween-20 (assay buffer) at multiple serial dilutions for 1 h at
room temperature. For detection of bound mAb FLC, heavy chains and whole IgGs, plates were
subsequently incubated with 0.1 µg/mL HRP-labeled goat anti-mouse κ light chain Ab (Southern
Biotech, Birmingham, AL 35260, UK), diluted in assay buffer for 1 h at room temperature. For detection
of mAb heavy chains, 0.1 µg/mL HRP-labeled goat anti-mouse IgG/IgM H+L Ab (Jackson Labs,
Bar Harbor, ME, USA) was used. Finally, TMB was used as a substrate for the enzymatic reaction,
terminated by adding 1 M H2 SO4 after 23 min in the case of Ab FLC assaying or after 3 min in all other
cases. Between incubation steps, wells were washed three times with PBS/0.05% Tween-20. To evaluate
the binding of FLC to OVA 323-339 peptide, plate wells were coated with OVA 323-339 peptide at a
concentration of 10 µg/mL, and assay was developed as above. To compare binding of FLC to native
OVA and OVA tryptic peptides, plate wells were coated with OVA preparations at a concentration of
100 µg/mL, and the assay was performed as above, but the reaction was stopped by adding 1 M H3
PO4 after 8 min.
4.11. ELISA for Assessment of Binding to Native OVA, OVA Tryptic Peptides, or OVA 323-339 Peptide by
Either JHneg/neg Mouse Exosomes Coated with Anti-OVA mAb FLC or Wild Type Mouse Exosomes
Plate wells were coated with either native OVA, OVA tryptic peptides or OVA 323-339 peptide,
all at a concentration of 100 µg/mL overnight at 4 ◦C and then blocked with 2% BSA for 2 h at room
temperature. Then exosome samples (approximately 5 × 109 exosomes per well) were added to
particular wells and incubated overnight at 4 ◦C. After washing with 0.1% BSA in PBS, 100 µL/well of
rat monoclonal IgG antibody anti-mouse CD9 (BD Biosciences, Franklin Lakes, NJ, USA) was added
at a concentration of 4 µg/mL and plate was incubated for 2 h at room temperature. After washing,
100 µL/well of HRP-conjugated rabbit anti-rat IgG antibody (Invitrogen, ThermoFisher, Waltham, MA,
USA) was added at a concentration of 2 µg/mL and plate was incubated for 1 h at room temperature.
After extensive washing, 100 µL/well of TMB substrate was added and the reaction was terminated
after 8 min by adding 50 µL/well of 1 M H3 PO4.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/15/
5540/s1. Figure S1. The general scheme of Ag immunization and challenge testing of mice administered ID with
ovalbumin (OVA) without an adjuvant to induce DTH responses. Figure S2. DTH induced by ID immunization
with OVA is prevented by prior IV injection of high doses of OVA-linked autologous RBC that induce tolerance to
OVA, due to suppressor T cells producing exosomes able to inhibit adoptive cell transfer of OVA-immune DTH.
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